Catalyst Pharmaceuticals (NASDAQ:CPRX) Cut to Buy at StockNews.com

StockNews.com downgraded shares of Catalyst Pharmaceuticals (NASDAQ:CPRX) from a strong-buy rating to a buy rating in a report issued on Saturday.

Several other brokerages have also issued reports on CPRX. HC Wainwright lifted their price target on Catalyst Pharmaceuticals from $30.00 to $35.00 and gave the company a “buy” rating in a report on Friday. Bank of America reissued a “buy” rating and issued a $30.00 target price on shares of Catalyst Pharmaceuticals in a research report on Thursday, January 9th. Truist Financial raised their price target on shares of Catalyst Pharmaceuticals from $30.00 to $36.00 and gave the company a “buy” rating in a report on Monday, November 11th. Finally, Stephens assumed coverage on shares of Catalyst Pharmaceuticals in a report on Monday, November 18th. They issued an “overweight” rating and a $35.00 price objective for the company. Eight research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company presently has an average rating of “Buy” and an average price target of $32.86.

Catalyst Pharmaceuticals Trading Up 1.3 %

CPRX opened at $22.21 on Friday. The stock has a fifty day moving average price of $21.77 and a 200 day moving average price of $20.02. Catalyst Pharmaceuticals has a 1 year low of $13.12 and a 1 year high of $24.27. The stock has a market cap of $2.65 billion, a price-to-earnings ratio of 18.82, a PEG ratio of 3.35 and a beta of 0.79.

Insider Buying and Selling

In other news, Director Molly Harper sold 17,500 shares of the firm’s stock in a transaction on Wednesday, November 27th. The shares were sold at an average price of $22.00, for a total value of $385,000.00. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Also, insider Steve Miller sold 50,000 shares of the business’s stock in a transaction on Tuesday, December 10th. The stock was sold at an average price of $21.93, for a total transaction of $1,096,500.00. Following the transaction, the insider now directly owns 686,996 shares in the company, valued at $15,065,822.28. This trade represents a 6.78 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 79,500 shares of company stock worth $1,754,140 in the last quarter. 11.00% of the stock is currently owned by company insiders.

Institutional Trading of Catalyst Pharmaceuticals

Hedge funds and other institutional investors have recently bought and sold shares of the stock. GAMMA Investing LLC lifted its stake in shares of Catalyst Pharmaceuticals by 62.1% in the third quarter. GAMMA Investing LLC now owns 1,778 shares of the biopharmaceutical company’s stock valued at $35,000 after buying an additional 681 shares during the period. nVerses Capital LLC acquired a new position in Catalyst Pharmaceuticals in the 3rd quarter valued at approximately $50,000. Larson Financial Group LLC lifted its position in shares of Catalyst Pharmaceuticals by 27,218.2% in the 3rd quarter. Larson Financial Group LLC now owns 3,005 shares of the biopharmaceutical company’s stock worth $60,000 after acquiring an additional 2,994 shares during the period. Meeder Asset Management Inc. acquired a new stake in shares of Catalyst Pharmaceuticals during the 2nd quarter worth approximately $70,000. Finally, Quantbot Technologies LP bought a new stake in shares of Catalyst Pharmaceuticals during the third quarter valued at approximately $151,000. 79.22% of the stock is currently owned by institutional investors and hedge funds.

About Catalyst Pharmaceuticals

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.